Elite in Cholangiocarcinoma (Bile Duct Cancer)

Nobumasa Mizuno

Nagoya, JP 
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Nagoya, JP 
OverviewLocationsClinical Research

Overview

Nobumasa Mizuno practices in Nagoya, Japan. Mizuno is rated as an Elite expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Their top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Islet Cell Tumor, Endoscopy, and Gastrostomy.

Their clinical research consists of co-authoring 204 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 17 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Locations

Nagoya, Japan
Other Locations
Okazaki, Japan
Sawara, 8140001, Japan
Hiroshima, 7348553, Japan
Tokyo, Japan
Yayoi, 1138657, Japan
Gifu-shi, 5011194, Japan
Minami, Japan
Shizuoka, 4118777, Japan
Sakawa, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2

204 Total Publications

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mizuno's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 39 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile